Can a common muscle relaxant make radiation deadlier for rectal cancer?

NCT ID NCT06834126

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This early-stage trial tests whether adding the drug papaverine to standard radiation therapy can safely improve treatment for locally advanced rectal cancer. Papaverine may help by reducing oxygen starvation inside tumors, which often makes radiation less effective. The study enrolls about 36 adults with stage II or III rectal cancer to find the best dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
papaverine combined with radiation therapy
What this could lead to
If it works, this could point toward a way to boost radiation's ability to kill rectal cancer cells, potentially improving outcomes without more aggressive surgery or chemotherapy.
What could go wrong
This is an early phase 1 trial with only 36 participants, focused on safety and dosing. It is too small to prove effectiveness, and papaverine may cause side effects or fail to improve radiation response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.